Britt K Erickson1, Omar Najjar2, Shari Damast3, Adriana Blakaj3, Joan Tymon-Rosario4, Maryam Shahi5, Alessandro Santin4, Molly Klein6, Michelle Dolan6, Ashley Cimino-Mathews5, Natalia Buza7, J Stuart Ferriss2, Rebecca L Stone2, Mahmoud Khalifa6, Amanda N Fader2. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology University of Minnesota, Minneapolis, MN, USA. Electronic address: bkeric@umn.edu. 2. Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, MD, USA. 3. Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA. 4. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT, USA. 5. Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 6. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA. 7. Department of Pathology, Yale School of Medicine, New Haven, CT, USA.
Abstract
BACKGROUND: Human epidermal growth factor receptor 2 (HER2) has emerged as an important prognostic and therapeutic target in advanced stage and recurrent uterine serous carcinoma (USC). The significance of tumoral HER2 expression in early-stage disease has not been established. METHODS: This multi-center cohort study included women with stage I USC treated from 2000 to 2019. Demographic, treatment, recurrence, and survival data were collected. Immunohistochemistry (IHC) was performed for HER2 and scored 0-3+. Equivocal IHC results (2+) were further tested with fluorescence in-situ hybridization (FISH). HER2 positivity was defined as 3+ IHC or FISH positive. RESULTS: One hundred sixty-nine patients with stage I USC were tested for HER2; 26% were HER2-positive. There were no significant differences in age, race, stage, adjuvant therapy, or follow-up duration between the HER2-positive and negative cohorts. Presence of lymph-vascular space invasion was correlated with HER2-positive tumors (p = .003). After a median follow-up of 50 months, there were 43 (25.4%) recurrences. There were significantly more recurrences in the HER2-positive cohort (50.0% vs 16.8%, p < .001). HER2 positive tumors were associated with worse progression-free (PFS) and overall survival (OS) (p < .001 and p = .024). On multivariate analysis, HER2 positive tumors were associated with inferior PFS (aHR 3.50, 95%CI 1.84-6.67; p < .001) and OS (aHR 2.00, 95%CI 1.04-3.88; p = .039) compared to HER2-negative tumors. CONCLUSIONS: Given its significant association with worse recurrence and survival outcomes, HER2 positivity appears to be a prognostic biomarker in women with stage I uterine serous carcinoma. These data provide support for clinical trials with anti-HER2-directed therapy in early-stage disease.
BACKGROUND:Human epidermal growth factor receptor 2 (HER2) has emerged as an important prognostic and therapeutic target in advanced stage and recurrent uterine serous carcinoma (USC). The significance of tumoralHER2 expression in early-stage disease has not been established. METHODS: This multi-center cohort study included women with stage I USC treated from 2000 to 2019. Demographic, treatment, recurrence, and survival data were collected. Immunohistochemistry (IHC) was performed for HER2 and scored 0-3+. Equivocal IHC results (2+) were further tested with fluorescence in-situ hybridization (FISH). HER2 positivity was defined as 3+ IHC or FISH positive. RESULTS: One hundred sixty-nine patients with stage I USC were tested for HER2; 26% were HER2-positive. There were no significant differences in age, race, stage, adjuvant therapy, or follow-up duration between the HER2-positive and negative cohorts. Presence of lymph-vascular space invasion was correlated with HER2-positive tumors (p = .003). After a median follow-up of 50 months, there were 43 (25.4%) recurrences. There were significantly more recurrences in the HER2-positive cohort (50.0% vs 16.8%, p < .001). HER2 positive tumors were associated with worse progression-free (PFS) and overall survival (OS) (p < .001 and p = .024). On multivariate analysis, HER2 positive tumors were associated with inferior PFS (aHR 3.50, 95%CI 1.84-6.67; p < .001) and OS (aHR 2.00, 95%CI 1.04-3.88; p = .039) compared to HER2-negative tumors. CONCLUSIONS: Given its significant association with worse recurrence and survival outcomes, HER2 positivity appears to be a prognostic biomarker in women with stage I uterine serous carcinoma. These data provide support for clinical trials with anti-HER2-directed therapy in early-stage disease.
Authors: Alessandro D Santin; Stefania Bellone; Sue Van Stedum; Wendy Bushen; Michela Palmieri; Eric R Siegel; Luis E De Las Casas; Juan J Roman; Alexander Burnett; Sergio Pecorelli Journal: Cancer Date: 2005-10-01 Impact factor: 6.860
Authors: Carlton L Schwab; Diana P English; Dana M Roque; Stefania Bellone; Salvatore Lopez; Emiliano Cocco; Roberta Nicoletti; Thomas J Rutherford; Peter E Schwartz; Alessandro D Santin Journal: Gynecol Oncol Date: 2014-08-12 Impact factor: 5.482
Authors: Alessandro D Santin; Stefania Bellone; Murat Gokden; Michela Palmieri; Donna Dunn; Jamshed Agha; Juan J Roman; Laura Hutchins; Sergio Pecorelli; Timothy O'Brien; Martin J Cannon; Groesbeck P Parham Journal: Clin Cancer Res Date: 2002-05 Impact factor: 12.531
Authors: Christiane Knuefermann; Yang Lu; Bolin Liu; Weidong Jin; Ke Liang; Ling Wu; Mathias Schmidt; Gordon B Mills; John Mendelsohn; Zhen Fan Journal: Oncogene Date: 2003-05-22 Impact factor: 9.867
Authors: Amanda N Fader; Dana M Roque; Eric Siegel; Natalia Buza; Pei Hui; Osama Abdelghany; Setsuko K Chambers; Angeles Alvarez Secord; Laura Havrilesky; David M O'Malley; Floor Backes; Nicole Nevadunsky; Babak Edraki; Dirk Pikaart; William Lowery; Karim S ElSahwi; Paul Celano; Stefania Bellone; Masoud Azodi; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Peter E Schwartz; Alessandro D Santin Journal: J Clin Oncol Date: 2018-03-27 Impact factor: 44.544
Authors: Amanda Nickles Fader; Richard D Drake; David M O'Malley; Heidi E Gibbons; Warner K Huh; Laura J Havrilesky; Paola A Gehrig; Erin Tuller; Allison E Axtell; Kristine M Zanotti Journal: Cancer Date: 2009-05-15 Impact factor: 6.860
Authors: Antonio C Wolff; M Elizabeth Hale Hammond; Kimberly H Allison; Brittany E Harvey; Pamela B Mangu; John M S Bartlett; Michael Bilous; Ian O Ellis; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Lisa M McShane; Mitchell Dowsett Journal: Arch Pathol Lab Med Date: 2018-05-30 Impact factor: 5.686
Authors: Jonathan Black; Gulden Menderes; Stefania Bellone; Carlton L Schwab; Elena Bonazzoli; Francesca Ferrari; Federica Predolini; Christopher De Haydu; Emiliano Cocco; Natalia Buza; Pei Hui; Serena Wong; Salvatore Lopez; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Babak Litkouhi; Peter E Schwartz; Peter Goedings; Patrick H Beusker; Miranda M C van der Lee; C Marco Timmers; Wim H A Dokter; Alessandro D Santin Journal: Mol Cancer Ther Date: 2016-06-02 Impact factor: 6.009
Authors: Michael D Toboni; Elena Lomonosova; Shaina F Bruce; Jo'an I Tankou; Mary M Mullen; Angela Schab; Alyssa Oplt; Hollie Noia; Danny Wilke; Lindsay M Kuroki; Andrea R Hagemann; Carolyn K McCourt; Premal H Thaker; Matthew A Powell; Dineo Khabele; David G Mutch; Katherine C Fuh Journal: Cancers (Basel) Date: 2021-11-23 Impact factor: 6.639
Authors: Elizabeth B Jeans; William G Breen; Trey C Mullikin; Brittany A Looker; Andrea Mariani; Gary L Keeney; Michael G Haddock; Ivy A Petersen Journal: Int J Gynecol Cancer Date: 2021-02-09 Impact factor: 3.437